Literature DB >> 28275245

Prevalence of Fabry disease and GLA c.196G>C variant in Japanese stroke patients.

Kiyoshiro Nagamatsu1,2, Yoshiki Sekijima1,3, Katsuya Nakamura1, Kimitoshi Nakamura4, Kiyoko Hattori4, Masao Ota5, Yusaku Shimizu2, Fumio Endo4, Shu-Ichi Ikeda1,3.   

Abstract

Fabry disease is an important underlying disease in young cryptogenic stroke patients. However, little is known regarding the frequency of Fabry disease in the general stroke population, especially in elderly patients. A total of 588 stroke patients (61.7% men; average age 74.1±12.5 years) were enrolled in this prospective study. Blood samples were obtained to produce blood spots to determine α-galactosidase A (α-GalA) activity and for GLA gene analysis. One 65-year-old female patient had a known GLA gene mutation, c.2T>C (p.M1T), causing Fabry disease. Five male patients and two female patients had GLA c.196G>C (p.E66Q) variant, which is not associated with the full clinical manifestations of Fabry disease. The allele frequency of GLA c.196G>C was significantly higher in male patients with small-vessel occlusion (odds ratio 3.95, P=0.048) and non-cardioembolism (odds ratio 4.08, P=0.012) than that in the general Japanese population. Fabry disease is rare in the general Japanese stroke population. However, screening identified one elderly female patient with Fabry disease. GLA c.196G>C variant is a genetic risk factor for cerebral small-vessel occlusion and non-cardioembolism in Japanese males but not in females.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28275245     DOI: 10.1038/jhg.2017.31

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  30 in total

1.  Fabry disease: enzymatic diagnosis in dried blood spots on filter paper.

Authors:  N A Chamoles; M Blanco; D Gaggioli
Journal:  Clin Chim Acta       Date:  2001-06       Impact factor: 3.786

2.  A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population.

Authors:  Miroslav Merta; Jana Reiterova; Jana Ledvinova; Helena Poupetová; Robert Dobrovolny; Romana Rysavá; Dita Maixnerová; Jan Bultas; Jirí Motán; Jitka Slivkova; Doris Sobotova; Jana Smrzova; Vladimir Tesar
Journal:  Nephrol Dial Transplant       Date:  2006-10-13       Impact factor: 5.992

3.  No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.

Authors:  Masahisa Kobayashi; Toya Ohashi; Takahiro Fukuda; Tomoyoshi Yanagisawa; Takayuki Inomata; Takashi Nagaoka; Teruo Kitagawa; Yoshikatsu Eto; Hiroyuki Ida; Eiji Kusano
Journal:  Mol Genet Metab       Date:  2012-10-24       Impact factor: 4.797

4.  Zurich Fabry study - prevalence of Fabry disease in young patients with first cryptogenic ischaemic stroke or TIA.

Authors:  H Sarikaya; M Yilmaz; N Michael; A R Miserez; B Steinmann; R W Baumgartner
Journal:  Eur J Neurol       Date:  2012-06-11       Impact factor: 6.089

5.  Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.

Authors:  M Tanaka; T Ohashi; M Kobayashi; Y Eto; N Miyamura; K Nishida; E Araki; K Itoh; K Matsushita; M Hara; K Kuwahara; T Nakano; N Yasumoto; H Nonoguchi; K Tomita
Journal:  Clin Nephrol       Date:  2005-10       Impact factor: 0.975

6.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

7.  Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy.

Authors:  Lorenzo Monserrat; Juan Ramón Gimeno-Blanes; Francisco Marín; Manuel Hermida-Prieto; Antonio García-Honrubia; Inmaculada Pérez; Xusto Fernández; Rosario de Nicolas; Gonzalo de la Morena; Eduardo Payá; Jordi Yagüe; Jesús Egido
Journal:  J Am Coll Cardiol       Date:  2007-12-18       Impact factor: 24.094

8.  Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.

Authors:  Shoichiro Nakao; Chihaya Kodama; Toshihiro Takenaka; Akihiro Tanaka; Yuichiro Yasumoto; Aichi Yoshida; Tamotsu Kanzaki; Annette L D Enriquez; Christine M Eng; Hiromitsu Tanaka; Chuwa Tei; Robert J Desnick
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

9.  p.E66Q mutation in the GLA gene is associated with a high risk of cerebral small-vessel occlusion in elderly Japanese males.

Authors:  K Nakamura; Y Sekijima; K Nakamura; K Hattori; K Nagamatsu; Y Shimizu; M Yazaki; A Sakurai; F Endo; Y Fukushima; S-I Ikeda
Journal:  Eur J Neurol       Date:  2013-05-31       Impact factor: 6.089

10.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

View more
  3 in total

1.  High-risk screening for Anderson-Fabry disease in patients with cardiac, renal, or neurological manifestations.

Authors:  Naoki Nakagawa; Jun Sawada; Naka Sakamoto; Toshiharu Takeuchi; Fumihiko Takahashi; Jun-Ich Maruyama; Ken Momosaki; Kimitoshi Nakamura; Fumio Endo; Naoyuki Hasebe
Journal:  J Hum Genet       Date:  2019-06-19       Impact factor: 3.172

2.  Characteristics of Neurological Symptoms in Adult Japanese Patients with Fabry Disease.

Authors:  Jun Sawada; Naoki Nakagawa; Kohei Kano; Tsukasa Saito; Takayuki Katayama; Takaaki Sawada; Ken Momosaki; Kimitoshi Nakamura; Naoyuki Hasebe
Journal:  Intern Med       Date:  2021-01-15       Impact factor: 1.271

3.  Nationwide screening for Fabry disease in unselected stroke patients.

Authors:  Aleš Tomek; Reková Petra; Jaroslava Paulasová Schwabová; Anna Olšerová; Miroslav Škorňa; Miroslava Nevšímalová; Libor Šimůnek; Roman Herzig; Štěpánka Fafejtová; Petr Mikulenka; Alena Táboříková; Jiří Neumann; Richard Brzezny; Helena Sobolová; Jan Bartoník; Daniel Václavík; Marta Vachová; Karel Bechyně; Hana Havlíková; Tomáš Prax; Daniel Šaňák; Irena Černíková; Iva Ondečková; Petr Procházka; Jan Rajner; Miroslav Škoda; Jan Novák; Ondřej Škoda; Michal Bar; Robert Mikulík; Gabriela Dostálová; Aleš Linhart
Journal:  PLoS One       Date:  2021-12-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.